• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by JanOne Inc. (Amendment)

    2/3/22 3:48:17 PM ET
    $JAN
    Get the next $JAN alert in real time by email
    SC 13G/A 1 g082595_sch13ga.htm SC 13G/A

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    JanOne Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    03814F205

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

     

      

    CUSIP No. 03814F205   13G   Page 2 of 9 Pages
       
    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Ionic Ventures, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☒
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    0

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    0

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%
    12. TYPE OF REPORTING PERSON (see instructions)

    OO

      

     

     

      

    CUSIP No. 03814F205   13G   Page 3 of 9 Pages
       
    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Brendan O’Neil
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☒
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    0
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%
    12. TYPE OF REPORTING PERSON (see instructions)

    IN

      

     

     

      

    CUSIP No. 03814F205   13G   Page 4 of 9 Pages
       
    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Keith Coulston
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☒
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    0
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%
    12. TYPE OF REPORTING PERSON (see instructions)

    IN

      

     

     

      

    CUSIP No. 03814F205   13G   Page 5 of 9 Pages

     

    Item 1(a). Name of Issuer:

     

    JanOne Inc. (the “Issuer”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    The Issuer’s principal executive offices are located at 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119.

     

    Item 2(a). Names of Persons Filing:

     

    This statement is filed by:
       
      (i) Ionic Ventures LLC, a California limited liability company (“Ionic”);
       
      (ii) Brendan O’Neil (“Mr. O’Neil”); and
       
      (iii)  Keith Coulston (“Mr. Coulston”).

     

    The foregoing persons are hereinafter sometimes collectively referred to as the (“Reporting Persons”). Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.  

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is 3053 Fillmore St, Suite 256 San Francisco, CA 94123.

     

    Item 2(c). Citizenship:

     

    Ionic is a limited liability company organized under the laws of California. Each of Mr. O’Neil and Mr. Coulston is a citizen of the United States.

     

    Item 2(d). Title of Class of Securities:

     

    The title of the class of securities to which this statement relates is the Common Stock of the Issuer, $0.001 par value per share (the “Common Stock”).

     

    Item 2(e). CUSIP Number:

     

    03814F205 

     

     

      

    CUSIP No. 03814F205   13G   Page 6 of 9 Pages

     

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    (a) Amount Beneficially owned:

     

    ●Ionic – 0

     

    ●Mr. O’Neil – 0

     

    ●Mr. Coulston – 0

     

    (b) Percent of class:

     

    ●Ionic – 0%

     

    ●Mr. O’Neil – 0%

     

    ●Mr. Coulston – 0%

     

     (c) Number of shares as to which the Report Person has:

     

    ●Ionic

     

    (i)Sole power to vote or direct the vote - 0

     

    (ii)Shared power to vote or direct the vote - 0

     

    (iii)Sole power to dispose or to direct the disposition of - 0

     

    (iv)Shared power to dispose or to direct the disposition of - 0

     

    ●Mr. O’Neil

     

    (i)Sole power to vote or direct the vote - 0

     

    (ii)Shared power to vote or direct the vote - 0

     

    (iii)Sole power to dispose or to direct the disposition of - 0

     

    (iv)Shared power to dispose or to direct the disposition of - 0

     

    ●Mr. Coulston

     

    (i)Sole power to vote or direct the vote - 0

     

    (ii)Shared power to vote or direct the vote - 0

     

    (iii)Sole power to dispose or to direct the disposition of - 0

     

    (iv)Shared power to dispose or to direct the disposition of - 0

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

      

     

     

      

    CUSIP No. 03814F205   13G   Page 7 of 9 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

      

     

     

      

    CUSIP No. 03814F205   13G   Page 8 of 9 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 2, 2022 IONIC VENTURES, LLC
       
      /s/ Keith Coulston
      Name: Keith Coulston
      Title: Partner
       
      /s/ Brendan O’Neil
      Brendan O’Neil
       
      /s/ Keith Coulston
      Keith Coulston

      

     

     

      

    CUSIP No. 03814F205   13G   Page 9 of 9 Pages

     

    EXHIBIT 1

     

    JOINT FILING AGREEMENT

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

     

    Date: February 2, 2022 IONIC VENTURES, LLC
       
      /s/ Keith Coulston
      Name: Keith Coulston
      Title: Partner
       
      /s/ Brendan O’Neil
      Brendan O’Neil
       
      /s/ Keith Coulston
      Keith Coulston

     

     

    Get the next $JAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Sandstrom Katherine M

    3 - Janus Living, Inc. (0002100805) (Issuer)

    3/20/26 6:51:17 PM ET
    $JAN

    SEC Form 3 filed by new insider Porter Tracy A

    3 - Janus Living, Inc. (0002100805) (Issuer)

    3/20/26 6:50:21 PM ET
    $JAN

    SEC Form 3 filed by new insider Patadia Ankit B.

    3 - Janus Living, Inc. (0002100805) (Issuer)

    3/20/26 6:48:16 PM ET
    $JAN

    $JAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE Content Update: Senior Housing REIT Janus Living to Make Public Debut

    NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, March 20, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on March 20thMarkets are lower Friday morning after Israeli Prime Minister Benjamin Netanyahu said his country was assisting the U.S. in reopening the Strait of Hormuz.Janus Living (NYSE:JAN) will begin trading on the NYSE today and celebrates its IPO on-site this morning.Guardian Metal Resources CEO & Executive Director Olive

    3/20/26 8:55:00 AM ET
    $ICE
    $JAN
    Investment Bankers/Brokers/Service
    Finance

    Healthpeak Properties and Janus Living Announce Pricing of Upsized $840 Million Janus Living Initial Public Offering

    Healthpeak Properties, Inc. (NYSE:DOC) ("Healthpeak") and Janus Living, Inc. ("Janus Living") announced the pricing of Janus Living's upsized initial public offering ("IPO") of 42,000,000 shares of Janus Living Class A-1 common stock at a price to the public of $20.00 per share. In addition, Janus Living has granted the underwriters a 30-day option to purchase up to an additional 6,300,000 shares of its Class A-1 common stock at the initial public offering price, less the underwriting discount. Janus Living's Class A-1 common stock is expected to begin trading on the New York Stock Exchange on March 20, 2026 under the ticker symbol "JAN." The IPO is expected to close on March 23, 2026, subj

    3/19/26 4:35:00 PM ET
    $DOC
    $JAN
    Real Estate Investment Trusts
    Real Estate

    ALT5 Sigma Corporation Partners With Hashtag Influencer to Enable Cryptocurrency Payment Processing for Influencer Marketing

    LAS VEGAS, NV / ACCESSWIRE / January 15, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a prominent innovator in the cryptocurrency sector, is pleased to announce a partnership with Hashtag Influencer, an advanced AI-powered SocialFi platform. This collaboration aims to enhance the influencer marketing landscape by enabling influencers in the gig economy to seamlessly and compliantly accept cryptocurrency payments for advertising deals with brands through social media platforms such as Instagram, Facebook, YouTube, and LinkedIn."While much attention has been given to the adoption of blockchain by traditional institutions, collaborating with innovators such as Hashtag Influencer-a forthcoming A

    1/15/25 7:00:00 AM ET
    $ALTS
    $JAN
    Finance: Consumer Services
    Finance

    $JAN
    SEC Filings

    View All

    SEC Form S-8 filed by JanOne Inc.

    S-8 - Janus Living, Inc. (0002100805) (Filer)

    3/20/26 8:18:24 AM ET
    $JAN

    SEC Form CERT filed by JanOne Inc.

    CERT - Janus Living, Inc. (0002100805) (Filer)

    3/20/26 6:14:23 AM ET
    $JAN

    SEC Form EFFECT filed by JanOne Inc.

    EFFECT - Janus Living, Inc. (0002100805) (Filer)

    3/20/26 12:15:09 AM ET
    $JAN

    $JAN
    Leadership Updates

    Live Leadership Updates

    View All

    ALT5 Sigma Welcomes FinTech Executive, Ron Pitters to Its Board of Directors

    LAS VEGAS, NV / ACCESSWIRE / November 6, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a fintech innovator providing next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and secure storage of digital assets, is pleased to announce the appointment of Mr. Ron Pitters to its Board of Directors."We are thrilled to welcome industry veteran, Ron Pitters, to our Board. With a unique blend of experience in both traditional finance and disruptive blockchain technologies, Ron brings invaluable insights. His proven track record, spanning from startups to multinational corporations, makes him a fantastic addition to our team,"

    11/6/24 8:30:00 AM ET
    $ALTS
    $JAN
    Finance: Consumer Services
    Finance

    JanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 Sigma

    LAS VEGAS, June 26, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr. Vay Tham as its Chief Revenue Officer and President of ALT5 Sigma, Inc., its wholly-owned subsidiary. Mr. Tham brings extensive experience in capital markets, particularly in technology sectors, spanning over 25 years. His career includes roles in research, investment banking, and finance, notably and most recently as Managing Director and Head of Technology Investment Banking at PI Financial Corp. (Ventum Financial).

    6/26/24 7:30:00 AM ET
    $JAN

    JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board

    LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D. to its Scientific Advisory Board (SAB). Dr. Goeders is considered one of the world's leaders on the role of stress in drug addiction.  Tony Isaac, President and Chief Executive Officer of JanOne, commented, "JanOne's mission is to develop non-addictive medications to treat diseases that cause severe pain, thereby m

    6/15/21 10:15:00 AM ET
    $JAN

    $JAN
    Financials

    Live finance-specific insights

    View All

    JanOne Announces Plan to Enhance Stockholder Value Through Strategic Realignment

    -The board has approved a strategic review of the biotech assets and ALT5 Sigma being the core focus going forward- -The company is intending a name and stock symbol change to reflect this decision- LAS VEGAS, July 10, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on fintech and healthcare, has announced plans to enhance stockholder value through a visionary strategic realignment, entailing a redeployment of biotech assets and a change of its name. The plan, unanimously approved by the company's board and following the May acquisi

    7/10/24 8:30:00 AM ET
    $JAN

    JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC

    The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a patent-pending, novel formulation of low-dose naltrexone. This all stock transaction has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M. The transaction includes restrictions on the maximum number of shares of preferred stock and common stock that can be i

    1/10/23 8:30:00 AM ET
    $JAN

    JanOne Inc. Acquires an Option for the Rights to a Worldwide, Exclusive License for a Novel Strategy for Treating Methamphetamine Use Disorder

    LAS VEGAS, Dec. 7, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - today announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO).  The agreement with LSU Health Shreveport, along with other intellectual property relating to TSPO's role in treating meth use disorder (MUD), provides JanOne Inc. with an opportunity to identify new drugs to enhance TSPO activity, and by doing so, reducing craving for meth. This new strategy for treating MUD w

    12/7/21 9:00:00 AM ET
    $JAN

    $JAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by JanOne Inc. (Amendment)

    SC 13G/A - JanOne Inc. (0000862861) (Subject)

    8/24/23 4:30:55 PM ET
    $JAN

    SEC Form SC 13G filed by JanOne Inc.

    SC 13G - JanOne Inc. (0000862861) (Subject)

    3/27/23 9:00:21 AM ET
    $JAN

    SEC Form SC 13G/A filed by JanOne Inc. (Amendment)

    SC 13G/A - JanOne Inc. (0000862861) (Subject)

    2/11/22 6:07:45 AM ET
    $JAN